Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring

K Oda, A Yamaguchi, N Matsumoto… - Therapeutic Drug …, 2024 - journals.lww.com
Background: Optimal cefepime dosing is a challenge because of its dose-dependent
neurotoxicity. This study aimed to determine individualized cefepime dosing for febrile …
相关文章

Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring

K Oda, A Yamaguchi, N Matsumoto… - Therapeutic drug …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Optimal cefepime dosing is a challenge because of its dose-dependent
neurotoxicity. This study aimed to determine individualized cefepime dosing for febrile …

Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring

K Oda, A Yamaguchi, N Matsumoto… - Therapeutic Drug …, 2022 - journals.lww.com
Background: Optimal cefepime dosing is a challenge because of its dose-dependent
neurotoxicity. This study aimed to determine individualized cefepime dosing for febrile …

Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring.

K Oda, A Yamaguchi, N Matsumoto… - Therapeutic Drug …, 2023 - europepmc.org
Background Optimal cefepime dosing is a challenge because of its dose-dependent
neurotoxicity. This study aimed to determine individualized cefepime dosing for febrile …